Cargando…

Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review

Lupus Nephritis (LN) is the most common manifestation of severe organ damage for systemic lupus erythematosus (SLE) patients. Severe active LN could result in acute kidney injury (AKI), which could even require Kidney Replacement Therapy (KRT). Therefore, there needs to be a more proactive and safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chengning, Zeng, Ming, Ge, Yifei, Liu, Kang, Xing, Changying, Mao, Huijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511409/
https://www.ncbi.nlm.nih.gov/pubmed/36172377
http://dx.doi.org/10.3389/fimmu.2022.977377
_version_ 1784797635588128768
author Zhang, Chengning
Zeng, Ming
Ge, Yifei
Liu, Kang
Xing, Changying
Mao, Huijuan
author_facet Zhang, Chengning
Zeng, Ming
Ge, Yifei
Liu, Kang
Xing, Changying
Mao, Huijuan
author_sort Zhang, Chengning
collection PubMed
description Lupus Nephritis (LN) is the most common manifestation of severe organ damage for systemic lupus erythematosus (SLE) patients. Severe active LN could result in acute kidney injury (AKI), which could even require Kidney Replacement Therapy (KRT). Therefore, there needs to be a more proactive and safe induction therapy to quickly and effectively control renal immune inflammation, maintain kidney function or reverse kidney damage. While multiple clinical studies have proven the efficacy and safety of Belimumab in treating SLE and LN, these studies have not included cases of severe LN requiring KRT. We observed the effectiveness and safety of Belimumab in treating four severe active LN patients undergoing KRT. With Belimumab administered at a dosage of 10mg/kg, all four patients were able to discontinue KRT with no adverse events (AEs) to date ultimately. These cases provided an excellent basis for the application of Belimumab combined with standard therapy to LN patients with a medium to severe kidney injury.
format Online
Article
Text
id pubmed-9511409
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95114092022-09-27 Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review Zhang, Chengning Zeng, Ming Ge, Yifei Liu, Kang Xing, Changying Mao, Huijuan Front Immunol Immunology Lupus Nephritis (LN) is the most common manifestation of severe organ damage for systemic lupus erythematosus (SLE) patients. Severe active LN could result in acute kidney injury (AKI), which could even require Kidney Replacement Therapy (KRT). Therefore, there needs to be a more proactive and safe induction therapy to quickly and effectively control renal immune inflammation, maintain kidney function or reverse kidney damage. While multiple clinical studies have proven the efficacy and safety of Belimumab in treating SLE and LN, these studies have not included cases of severe LN requiring KRT. We observed the effectiveness and safety of Belimumab in treating four severe active LN patients undergoing KRT. With Belimumab administered at a dosage of 10mg/kg, all four patients were able to discontinue KRT with no adverse events (AEs) to date ultimately. These cases provided an excellent basis for the application of Belimumab combined with standard therapy to LN patients with a medium to severe kidney injury. Frontiers Media S.A. 2022-09-12 /pmc/articles/PMC9511409/ /pubmed/36172377 http://dx.doi.org/10.3389/fimmu.2022.977377 Text en Copyright © 2022 Zhang, Zeng, Ge, Liu, Xing and Mao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhang, Chengning
Zeng, Ming
Ge, Yifei
Liu, Kang
Xing, Changying
Mao, Huijuan
Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review
title Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review
title_full Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review
title_fullStr Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review
title_full_unstemmed Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review
title_short Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review
title_sort effectiveness and safety of belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: a case report and literature review
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511409/
https://www.ncbi.nlm.nih.gov/pubmed/36172377
http://dx.doi.org/10.3389/fimmu.2022.977377
work_keys_str_mv AT zhangchengning effectivenessandsafetyofbelimumabcombinedwithstandardtherapyinsevereactivelupusnephritisrequiringkidneyreplacementtherapyacasereportandliteraturereview
AT zengming effectivenessandsafetyofbelimumabcombinedwithstandardtherapyinsevereactivelupusnephritisrequiringkidneyreplacementtherapyacasereportandliteraturereview
AT geyifei effectivenessandsafetyofbelimumabcombinedwithstandardtherapyinsevereactivelupusnephritisrequiringkidneyreplacementtherapyacasereportandliteraturereview
AT liukang effectivenessandsafetyofbelimumabcombinedwithstandardtherapyinsevereactivelupusnephritisrequiringkidneyreplacementtherapyacasereportandliteraturereview
AT xingchangying effectivenessandsafetyofbelimumabcombinedwithstandardtherapyinsevereactivelupusnephritisrequiringkidneyreplacementtherapyacasereportandliteraturereview
AT maohuijuan effectivenessandsafetyofbelimumabcombinedwithstandardtherapyinsevereactivelupusnephritisrequiringkidneyreplacementtherapyacasereportandliteraturereview